assessing high-risk aml
Published 4 years ago • 144 plays • Length 3:51Download video MP4
Download video MP3
Similar videos
-
2:41
onvansertib and decitabine in relapsed/refractory aml
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
5:36
venetoclax and azacitidine in mds patients
-
3:10
novel aml treament approaches
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
3:52
venetoclax & aml
-
25:03
life archives journal with me | backlogging in my memory keeping journal (midori a6 1d1p)
-
28:19
diagnosis: morphology, flow cytometry, cytogenetics, molecular testing, and risk-stratification
-
12:05
venetoclax combinations, safety and efficacy
-
4:22
the role of mrd in aml
-
6:19
harnessing apoptosis in aml
-
1:21
intensive therapy of older aml
-
5:31
the role of venetoclax in older patients with aml
-
1:51
thrombotic and bleeding complications in al amyloidosis
-
1:45
role for mrd assessment in al amyloidosis?
-
4:39
aml & mds: mac or ric?
-
5:42
immune checkpoint inhibitors in mds and aml
-
3:11
assessment of mrd in aml
-
3:13
final results of bright aml 1003
-
2:00
al amyloidosis: hot topics from isa 2020
-
1:47
flow identification and monitoring of leukemia stem cells
-
0:38
optimal time for allo-hsct in aml